# Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

> **NCT03785964** · PHASE3 · COMPLETED · sponsor: **SpringWorks Therapeutics, Inc.** · enrollment: 142 (actual)

## Conditions studied

- Desmoid Tumor
- Aggressive Fibromatosis

## Interventions

- **DRUG:** Nirogacestat oral tablet
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03785964
- **Lead sponsor:** SpringWorks Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-17
- **Primary completion:** 2022-04-07
- **Final completion:** 2024-10-17
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785964, "Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03785964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*